Status: Not yet recruiting
Phase 1 Trial of ACE723, A Dual-Payload Antibody Drug Conjugate, in Patients With Advanced HCC Who Have Failed or Progressed on Standard Systemic Therapy Containing ICIs
ACE723 is a dual-payload antibody drug conjugate targeting glypican-3 (GPC-3) that is under investigation for the treatment of unresectable or metastatic hepatocellular carcinoma (HCC).
Participants needed: 70
Trial details
Phase: Phase 1Age: 18-75Biological sex: AllType: InterventionalSponsor: Acepodia Biotech, Inc.Updated: Oct 6, 2026Locations: 2
Eligibility criteria
Males or females aged 18 to 75 years [+12]
Other types of hepatic malignancies, such as mixed cholangiocarcinoma/HCC, sarco... [+14]